Evidence map›Paper›PMID 40241163›Full record

ArticleArthritis research & therapy2025

Identifying two pathways to poor prognosis in patients with anti-MDA5 antibodies: insights from prognostic factor and cytokines analysis.

Aya Shimizu, Kazuhiro Kurasawa, Tomoka Hiyama, Sara Komatsu, Azusa Kikuchi, Yuhi Yoshida, Anna Hasegawa, Tomoyuki Miyao, Ayae Tanaka, Satoko Arai and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Aya ShimizuDepartment of Rheumatology, Dokkyo Medical University, 880 Kita-Kobayashi, Mibu, Tochigi, 321-0293, Japan.
Kazuhiro KurasawaDepartment of Rheumatology, Dokkyo Medical University, 880 Kita-Kobayashi, Mibu, Tochigi, 321-0293, Japan. kurasawa@dokkyomed.ac.jp.
Tomoka HiyamaDepartment of Rheumatology, Dokkyo Medical University, 880 Kita-Kobayashi, Mibu, Tochigi, 321-0293, Japan.
Sara KomatsuDepartment of Rheumatology, Dokkyo Medical University, 880 Kita-Kobayashi, Mibu, Tochigi, 321-0293, Japan.
Azusa KikuchiDepartment of Rheumatology, Dokkyo Medical University, 880 Kita-Kobayashi, Mibu, Tochigi, 321-0293, Japan.
Yuhi YoshidaDepartment of Rheumatology, Dokkyo Medical University, 880 Kita-Kobayashi, Mibu, Tochigi, 321-0293, Japan.
Anna HasegawaDepartment of Rheumatology, Dokkyo Medical University, 880 Kita-Kobayashi, Mibu, Tochigi, 321-0293, Japan.
Tomoyuki MiyaoDepartment of Rheumatology, Dokkyo Medical University, 880 Kita-Kobayashi, Mibu, Tochigi, 321-0293, Japan.
Ayae TanakaDepartment of Rheumatology, Dokkyo Medical University, 880 Kita-Kobayashi, Mibu, Tochigi, 321-0293, Japan.
Satoko AraiDepartment of Rheumatology, Dokkyo Medical University, 880 Kita-Kobayashi, Mibu, Tochigi, 321-0293, Japan.
Reika MaezawaDepartment of Rheumatology, Dokkyo Medical University, 880 Kita-Kobayashi, Mibu, Tochigi, 321-0293, Japan.
Masafumi ArimaDepartment of Rheumatology, Dokkyo Medical University, 880 Kita-Kobayashi, Mibu, Tochigi, 321-0293, Japan.
Kei IkedaDepartment of Rheumatology, Dokkyo Medical University, 880 Kita-Kobayashi, Mibu, Tochigi, 321-0293, Japan.

Funding

Japan Society for the Promotion of Science (JAPS) KAKENHI 21K08478
6 · The paper itself

Abstract

objectiveTo identify pathways linking cytokine abnormalities to mortality via prognostic factors in patients with anti-melanoma differentiation-associated protein 5 antibodies (anti-MDA5 Ab).

methodsThis study included patients with anti-MDA5 Ab whose serum was available. Serum cytokine levels were measured using a multiplex bead assay. Prognostic factors were identified using Cox regression and log-rank test. Prognostic factor groups were identified using principal component analysis (PCA) and factor and cluster analyses. The association between cytokine levels and prognostic factors (groups) was examined using PCA and correlation and path analyses. A prognosis-prediction model was developed using prognostic factors from the different groups.

resultsThirty-five patients were included in this study, of whom 31 had rapidly progressive interstitial lung disease (RP-ILD), and 14 died. We identified white blood cell (WBC), gamma-glutamyl transpeptidase (γ-GTP), lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin, and ILD-related factors (Krebs von den Lungen-6 [KL-6], surfactant protein D [SP-D], and CT score) as prognostic factors, in addition to von Willebrand factor and thrombomodulin. Two prognostic factor groups were found: Group 1 included WBC, CRP, and ILD-related factors, and Group 2 included ferritin, LDH, and γ-GTP. Both groups contributed to mortality. Group 1 was associated with IL-6, and Group 2 was related to IL-6, IL-10, and IP-10, and indirectly with TNF-α. A model using CRP (Group1) and γ-GTP (Group2) achieved an area under the curve of 0.84, which was not inferior to previously reported models.

conclusionsTwo pathways leading to poor prognosis were identified in anti-MDA5-Ab-positive patients, each marked by specific cytokine abnormalities.

Indexed as

AutoantibodiesCytokinesInterferon-Induced Helicase, IFIH1Lung Diseases, InterstitialAdultAgedBiomarkersFemaleHumansMaleMiddle AgedPrognosisAutoantibodiesBiomarkersCytokinesIFIH1 protein, humanInterferon-Induced Helicase, IFIH1Anti-MDA5 antibodyCytokinesDermatomyositisGroupingInterstitial lung diseasePrediction modelPrognostic factors

Identifiers

PMID40241163
PMCPMC12004667

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.